VIPOR Regimen for CNS-involved B-Cell Lymphoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial uses a combination of drugs called VIPOR-Nivo to treat adults with specific aggressive brain lymphomas that are hard to treat. The drugs work together to kill cancer cells and boost the immune system.
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications, but you cannot take strong CYP3A inhibitors/inducers or warfarin. It's best to discuss your current medications with the study team.
What safety data exists for the VIPOR Regimen components in humans?
Ibrutinib can cause bleeding and atrial fibrillation (irregular heartbeat), while venetoclax may lead to tumor lysis syndrome (a condition where cancer cells break down rapidly, potentially harming the kidneys). These side effects can be severe and may require dose adjustments or special monitoring.12345
What makes the VIPOR regimen unique for treating CNS-involved B-cell lymphoma?
The VIPOR regimen is unique because it combines multiple drugs, including ibrutinib, lenalidomide, obinutuzumab, prednisone, and venetoclax, which target different pathways involved in B-cell lymphoma. This combination aims to enhance treatment effectiveness by using a multi-faceted approach, potentially offering benefits over traditional single-agent therapies.16789
What data supports the effectiveness of the VIPOR regimen drugs for CNS-involved B-cell lymphoma?
Who Is on the Research Team?
Mark J Roschewski, M.D.
Principal Investigator
National Cancer Institute (NCI)
Are You a Good Fit for This Trial?
Adults aged 18+ with B-cell lymphoma in the CNS that's unresponsive to treatment, relapsed after treatment, or ineligible for standard therapy due to age or kidney function. Must have measurable disease and adequate organ/marrow function. Participants must not be pregnant, agree to use birth control, and can't have certain other cancers needing active treatment.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VIPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) in 21-day cycles for up to 6 cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Ibrutinib
- Lenalidomide
- Obinutuzumab
- Prednisone
- Venetoclax
Ibrutinib is already approved in European Union, United States, Canada, Japan for the following indications:
- Chronic lymphocytic leukemia
- Mantle cell lymphoma
- Waldenström's macroglobulinemia
- Marginal zone lymphoma
- Graft-versus-host disease
- Chronic lymphocytic leukemia/small lymphocytic lymphoma
- Mantle cell lymphoma
- Waldenström's macroglobulinemia
- Marginal zone lymphoma
- Graft-versus-host disease
- Chronic lymphocytic leukemia
- Mantle cell lymphoma
- Waldenström's macroglobulinemia
- Marginal zone lymphoma
- Chronic lymphocytic leukemia
- Mantle cell lymphoma
- Waldenström's macroglobulinemia
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor